Le cancer colorectal d’âge précoce : une perspective canadienne
Résumé
Au Canada, 92 % des cas de cancer colorectal surviennent chez des patients de plus de 50 ans. Par conséquent, la plupart des recherches sur le cancer colorectal et des efforts de détection précoce se sont traditionnellement concentrés sur les Canadiens plus âgés. L’épidémiologie du cancer colorectal au Canada est cependant en train de changer. Au cours des trente dernières années, nous avons observé une diminution considérable de l’incidence du cancer colorectal chez les patients de plus de 50 ans, alors que l’incidence chez les patients de moins de 50 ans a augmenté de façon alarmante. On estime que d’ici 2040, le cancer colorectal sera la principale cause de décès par cancer chez les personnes âgées de 20 à 49 ans. Cet article présentera une vue d’ensemble des caractéristiques uniques et des besoins particuliers en matière de soins des patients atteints d’un cancer colorectal apparaissant à un âge précoce (CCR-AP), et ce, d’une perspective canadienne. Sauf indication contraire, le terme CCR-AP désigne les personnes chez qui un cancer colorectal a été diagnostiqué avant l’âge de 50 ans.
Références
Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society: Canadian Cancer Statistics 2023. Toronto, ON, 2023
Brenner DR, Heer E, Sutherland RL et al. National trends in colorectal cancer incidence among older and younger adults in Canada. JAMA Network Open 2:e198090-e198090. 2019.
Rahib L, Smith BD, Aizenberg R etl. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Research. 2014; 74:2913-2921.
Zauber AG, Winawer SJ, O’Brien MJ et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366:687-696.
Murphy CC, Sandler RS, Sanoff HK. Decrease in incidence of colorectal cancer among individuals 50 years or older after recommendations for population-based screening. CGH. 2017;15:903-909. e6.
Patel SG, Karlitz JJ, Yen T et al. The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection. Lancet Gastroenterol Hepatol. 2022;7:262-274.
Yang Y, Du L, Shi D et al. Dysbiosis of human gut microbiome in young-onset colorectal cancer. Nature Communications. 2021;12:6757.
Murphy N, Jenab M, Gunter MJ. Adiposity and gastrointestinal cancers: epidemiology, mechanisms and future directions. Nat Rev Gastroenterol Heptaol. 2018;15:659-670.
Pearlman R, Frankel WL, Swanson B et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncology. 2017;3:464-471.
Green R, Green J, Buehler S et al. Very high incidence of familial colorectal cancer in Newfoundland: a comparison with Ontario and 13 other population-based studies. Familial Cancer. 2007;6:53-62.
Chang VC, Cotterchio M, De P.Risk factors for early-onset colorectal cancer: a population-based case–control study in Ontario, Canada. Cancer Causes & Control. 2021;32:1063-1083.
O’Sullivan DE, Sutherland RL, Town S et al. Risk factors for early-onset colorectal cancer: a systematic review and meta-analysis. Clin Gastro Hepatol. 2022;20:1229-1240. e5.
Liu P-H, Wu K, Ng K. Association of obesity with risk of early-onset colorectal cancer among women. JAMA Oncology. 2019;5:37-44.
Murphy CC, Singal AG, Baron JA. Decrease in incidence of young-onset colorectal cancer before recent increase. J Gastroenterol. 2018;155:1716-1719. e4.
Zhang Q, Berger FG, Love B et al. Maternal stress and early-onset colorectal cancer. Medical Hypotheses. 2018;121:152-159.
Cao Y, Nguyen LH, Tica S et al. Evaluation of birth by cesarean delivery and development of early-onset colorectal cancer. JAMA Network Open. 2023;6:e2310316-e2310316.
McDowell R, Perrott S, Murchie P et al. Oral antibiotic use and early-onset colorectal cancer: findings from a case-control study using a national clinical database. Br J Cancer. 2022;126:957-967.
Yuan C, Wang Q-L, Kim H et al. Being breastfed in infancy and risk of colorectal cancer and precursor sesions. Clin Gastroenterol Hepatol. 2023 Sep 6:S1542-3565(23)00673-0.
Cancer CPA: Colorectal cancer screening in Canada 2021/2022, 2022.
Davidson KW, Barry MJ, Mangione CM et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325:1965-1977.
Knudsen AB, Rutter CM, Peterse EF et al. Colorectal cancer screening: an updated modeling study for the US Preventive Services Task Force. JAMA. 2021;325:1998-2011.
Kalyta A, Ruan Y, Telford JJ et al. Association of reducing the recommended colorectal cancer screening age with cancer incidence, mortality, and costs in Canada using OncoSim. JAMA Oncology. 2023;9:1432-1436.
Raphael MJ, Wildgoose P, Servidio-Italiano F. Breaking down barriers to detection and care in early-age-onset colorectal cancer in Canada. MDPI, 2023.
Khangura SD, Spry C. Screening for colorectal cancer in individuals younger than 50 years. Canadian Journal of Health Technologies. 2023;3.
Hawks MK, Svarverud JE. Acute lower gastrointestinal bleeding: evaluation and management. AFP. 2020; 101:206-212.
Baronas V, Arif AA, Bhang E et al. Symptom burden and time from symptom onset to cancer diagnosis in patients with early-onset colorectal cancer: a multicenter retrospective analysis. 2023.
Castelo M, Paszat L, Hansen BE et al. Comparing time to diagnosis and treatment between younger and older adults with colorectal cancer: A population-based study. J Gastroenterol. 2023;164:1152-1164.
Chen FW, Sundaram V, Chew TA et al. Advanced-stage colorectal cancer in persons younger than 50 years not associated with longer duration of symptoms or time to diagnosis. Clin Gastroenterol Hepatol. 2017;15:728-737. e3.
Willauer AN, Liu Y, Pereira AA et al. Clinical and molecular characterization of early‐onset colorectal cancer. Cancer. 2019;125:2002-2010.
Rodriguez L, Brennan K, Karim S et al. Disease characteristics, clinical management, and outcomes of young patients with colon cancer: a population-based study. Clin Colorectal Cancer. 2018; 17:e651-e661.
O’Sullivan DE, Cheung WY, Boyne DJ et al. Treatment patterns and survival outcomes of early-onset colorectal cancer patients in Alberta, Canada: A population-based study. CTARC. 2022; 32:100585.
Baxter NN, Kennedy EB, Bergsland E et al. Adjuvant therapy for stage II colon cancer: ASCO guideline update. J Clin Oncol. 2022;40:892-910.
Group QC: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. The Lancet. 2007;370:2020-2029.
André T, Meyerhardt J, Iveson T et al. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol. 2020;21:1620-1629.
Fontana E, Meyers J, Sobrero A et al. Early-onset colorectal adenocarcinoma in the IDEA database: treatment adherence, toxicities, and outcomes with 3 and 6 months of adjuvant fluoropyrimidine and oxaliplatin. J Clin Oncol. 2021;39:4009-4019.
Gallois C, Shi Q, Meyers JP et al. Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials. J Clin Oncol. 2023 Feb 1;41(4):803-815.
Dossa F, Baxter NN. Changing the treatment paradigm for locally advanced rectal cancer. N Engl J Med. 2023 July;389(4):375-377.
Cercek A, Lumish M, Sinopoli J. PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer. N Engl J Med. 2022;386:2363-2376.
Chalabi M, Fanchi LF, Dijkstra KK et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nature Medicine. 2020;26:566-576.
Chalabi M, Verschoor Y, Van den Berg J et al.LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study. Annals of Oncology. 2022;33:S1389.
Blanke CD, Bot BM, Thomas DM et al. Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. J Clin Oncol. 2011;29:2781.
Stringer JM, Swindells EO, Zerafa N et al. Multidose 5-fluorouracil is highly toxic to growing ovarian follicles in mice. Toxicol Sci. 2018;166:97-107.
Levi M, Shalgi R, Brenner B et al. The impact of oxaliplatin on the gonads: from bedside to the bench. MHR: Basic Science of Reproductive Medicine. 2015;21:885-893.
Falk P, Severin M, Berglund Å et al. Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer. CTARC. 2022;31:100517.
Oktay K, Harvey BE, Partridge AH et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36:1994-2001.
Lambertini M, Ceppi M, Poggio F et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26:2408-2419.
Wallace W, Thomson A, Kelsey T. The radiosensitivity of the human oocyte. Hum Reprod. 2003;18:117-121.
Lee SJ, Schover LR, Partridge AH et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917-2931.
Mariani S, Chiloiro G, Villa P et al. Fertility preservation in chemo-radiotherapy for rectal cancer: A combined approach. Clinical and Translational Radiation Oncology. 2019;19:77-79.
Zwahlen DR, Bischoff LI, Gruber G et al. Estimation of second cancer risk after radiotherapy for rectal cancer: comparison of 3D conformal radiotherapy and volumetric modulated arc therapy using different high dose fractionation schemes. Radiat Oncol J. 2016;11:1-9.
Bryant CL, Lunniss PJ, Knowles CH et al. Anterior resection syndrome. Lancet Oncol. 2012;13:e403-e408.
Sun R, Dai Z, Zhang Y et al. The incidence and risk factors of low anterior resection syndrome (LARS) after sphincter-preserving surgery of rectal cancer: a systematic review and meta-analysis. Support Care Cancer. 2021;29:7249-7258.
Nguyen TH, Chokshi RV. Low anterior resection syndrome. Curr Gastroenterol Rep. 2020;22:1-8.
Garfinkle R, Ky A, Singh A et al. Financial and occupational impact of low anterior resection syndrome in rectal cancer survivors. Colorectal Dis. 2021; 23:1777-1784.
van der Valk MJ, van der Sande ME, Toebes RE et al. Importance of patient reported and clinical outcomes for patients with locally advanced rectal cancer and their treating physicians. Do clinicians know what patients want? EJSO. 2020;46:1634-1641.
LeBlanc K, Heerschap C, Martins L et al. The financial impact of living in Canada with an ostomy: a cross-sectional survey. JWOCN. 2019;46:505-512.
Leon-Carlyle M, Schmocker S, Victor JC et al. Prevalence of physiologic sexual dysfunction is high following treatment for rectal cancer: but is it the only thing that matters? Dis Colon Rectum. 2015;58:736-742.
Colorectal Cancer Alliance CC: Never Too Young Survery, 2022. Available at: https://www.ccalliance.org/about/never-too-young/survey
Cavestro GM, Mannucci A, Balaguer F, Hampel H, Kupfer SS, Repici A, Sartore-Bianchi A, Seppälä TT, Valentini V, Boland CR, Brand RE. Delphi initiative for early-onset colorectal cancer (DIRECt) international management guidelines. Clinical Gastroenterology and Hepatology. 2023 Mar 1;21(3):581-603.
Publié
Comment citer
Numéro
Rubrique
Licence
© Canadian Oncology Today 2024
Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
